Lynparza Approved to Treat Metastatic HER2-, BRCA+ BC

Options
Moderators
Moderators Member Posts: 25,912

Lynparza Approved to Treat Metastatic HER2-Negative Breast Cancer in Women With BRCA Mutations
January 12, 2018

On Jan. 12, 2018, the FDA approved Lynparza to treat metastatic HER2-negative breast cancer in women with a BRCA1 or BRCA2 mutation. Read more...

Categories